Can Adderall Cause Raynaud’s Syndrome?

Adderall and other amphetamine-based stimulants can trigger Raynaud’s phenomenon, the condition in which fingers or toes turn white, blue, and then red in response to cold or stress due to sudden narrowing of small blood vessels. The prescribing information for amphetamine and lisdexamfetamine lists Raynaud’s as an uncommon side effect, and a growing number of case reports and reviews have documented the connection. While the condition remains rare relative to the millions of people taking ADHD medications, the link is real enough that a large analysis of FDA adverse-event reports ranked lisdexamfetamine among the top five drugs most strongly associated with Raynaud’s reports.

How Stimulants Trigger Raynaud’s

Raynaud’s phenomenon happens when the tiny arteries supplying blood to your fingers and toes suddenly clamp down, temporarily starving those tissues of oxygen-rich blood. The classic color sequence, white to blue to red, reflects the progression from blood flow cutoff to deoxygenation to the rush of blood returning once the vessels relax. In many people, this happens without any identifiable cause (called primary Raynaud’s). When it is triggered by a medication, an autoimmune disease, or another external factor, it is classified as secondary Raynaud’s phenomenon.

Amphetamines, including the mixed amphetamine salts in Adderall and the prodrug lisdexamfetamine (Vyvanse), work by boosting levels of norepinephrine and dopamine in the brain. That same norepinephrine surge does not stay confined to the brain. Norepinephrine is the body’s main signal for constricting blood vessels, and when circulating levels rise, vessels throughout the body, including the small arteries in the fingers and toes, can tighten more aggressively than normal. A study drawing on FDA adverse-event data described this mechanism plainly: central nervous system stimulants like lisdexamfetamine and methylphenidate induce Raynaud’s primarily by inhibiting dopamine and norepinephrine reuptake.¹ In someone whose peripheral blood vessels are already prone to overreacting, that extra vasoconstrictor push can be enough to tip them into full Raynaud’s episodes.

How Common Is This Side Effect

By the standards of most drug side effects, stimulant-related Raynaud’s is uncommon. The prescribing information for lisdexamfetamine lists it in that category, and no large randomized controlled trials have measured its precise incidence.² What we have instead is a patchwork of case reports, small case series, and a couple of retrospective studies.

A 2025 systematic review combed through the medical literature and identified 61 documented cases of Raynaud’s syndrome linked to ADHD medications, drawn from 15 case reports, 5 case series, one retrospective case-control study, and one retrospective cohort study. The implicated drugs were methylphenidate (Ritalin, Concerta), dextroamphetamine and mixed amphetamine salts (Adderall), and more rarely atomoxetine (Strattera).³ Sixty-one cases across the entire published literature might sound trivial, but drug-related Raynaud’s is almost certainly underreported. Many patients never connect their cold, discolored fingers to their ADHD medication, and many doctors do not think to ask about it.

The FDA’s own adverse-event reporting system tells a more dramatic story when it comes to signal strength. An analysis of that database found that lisdexamfetamine had a reporting odds ratio of about 25 for Raynaud’s phenomenon, meaning reports of Raynaud’s were roughly 25 times more frequent with that drug than you would expect by chance across all drugs in the system. Methylphenidate came in at about 8 times the expected rate.¹ Those are disproportionality signals, not prevalence rates, so they do not tell you what percentage of Adderall users will develop Raynaud’s. But they do confirm that when Raynaud’s shows up in the adverse-event database, stimulant medications are disproportionately present.

What It Looks Like in Practice

The typical story involves someone who starts a stimulant for ADHD and, within days to weeks, begins noticing that their fingers turn white or bluish when exposed to cold. In one published case, a woman started on 10 mg of Adderall and developed daily Raynaud’s episodes within a single week of starting treatment.⁴ Episodes can also appear in the toes, though fingers are more common. The attacks tend to follow the classic triphasic color pattern and are often provoked by cold temperatures or emotional stress, just like non-drug-related Raynaud’s.

One detail worth noting: some people who develop Raynaud’s on stimulants already had mild cold sensitivity before starting the medication. The drug does not always create the problem from scratch. It can also unmask or worsen a tendency that was already there but not bothersome enough to notice. An earlier scoping review noted that the peripheral vascular problems seen with stimulants ranged from new-onset Raynaud’s attacks to worsening of existing cold sensitivity, and in some cases extended to acrocyanosis (persistent blue discoloration) or perniosis (chilblain-like lesions).⁵

Does It Go Away If You Stop the Medication

In many cases, yes. A case report of two patients on lisdexamfetamine found that stopping the medication led to resolution of Raynaud’s within a few days.² Across the broader literature, complete resolution of symptoms was observed in about half of the studies reviewed once the stimulant was stopped. Other patients saw improvement with dose reduction or with switching to a different medication.⁵

That “half of studies” figure is not as clean as it sounds. Case reports tend to document what the author found interesting, and resolution after stopping is a tidy narrative that attracts publication. Patients who stopped their medication and still had symptoms, or those who never stopped and managed to cope, are less likely to end up in a published report. Still, the pattern across multiple reports is encouraging: if the stimulant caused the problem, removing the stimulant often fixes it.

There is also evidence that the relationship between dose and symptoms is not all-or-nothing. In some documented cases, patients who moved to higher doses saw worsening of their vascular symptoms, while dose reduction brought improvement.⁶ This dose-dependent pattern makes pharmacological sense, since higher doses mean more norepinephrine in circulation and more pressure on peripheral vessels to constrict.

When Raynaud’s Becomes Serious

For most people who develop mild Raynaud’s episodes on a stimulant, the condition is more annoying than dangerous. Fingers turn colors, feel numb or painful for a few minutes, and then recover. But the medical literature also contains cases where things went much further. The systematic review of ADHD medication-associated Raynaud’s noted that a few cases progressed to ulceration, gangrene, and even the need for amputation or surgical revascularization.³

A separate case series focused specifically on patients taking an amphetamine analog described six individuals who developed severe peripheral vascular problems, including tissue loss and the need for lower extremity amputation. In that group, three out of four patients refused to stop the medication during follow-up.⁷ That last detail is striking. ADHD medications are effective and, for many people, life-changing. The prospect of giving them up because of a vascular side effect is genuinely difficult, and some patients make the calculation that the cognitive benefits outweigh the physical risks, even when those risks are severe. This makes ongoing monitoring especially important in anyone who develops circulatory symptoms on a stimulant.

Severe outcomes like tissue loss and amputation remain rare, and they tend to cluster in patients with other risk factors for poor circulation, including pre-existing autoimmune connective tissue disease, smoking, or prolonged use of high doses. But even a small number of catastrophic cases means clinicians need to take new Raynaud’s symptoms in a stimulant user seriously rather than dismissing them as a minor nuisance.

How Strong Is the Evidence That the Drug Caused It

Proving that a specific medication caused a side effect in a specific patient is harder than it sounds. With Raynaud’s and stimulants, we do not have any randomized controlled trials measuring the risk. What we have are observational reports and causality assessments applied case by case. The 2025 systematic review assessed 28 of its cases using the Naranjo criteria, a standardized tool for rating whether a drug caused an adverse event. Of those 28, a “possible” causative role was found in 13, “probable” in 13, and “definite” in 2.³

A “definite” rating on the Naranjo scale typically requires that the patient developed the problem on the drug, improved when it was stopped, and then developed the problem again when re-exposed. That full cycle rarely happens in real-world care because most doctors do not intentionally re-challenge a patient with a drug that already caused them vascular problems. So the low number of “definite” cases does not mean causation is weak; it means the bar for “definite” is high and ethically hard to meet. The fact that half of the assessed cases were rated “probable” is the more meaningful signal. Combined with the clear pharmacological mechanism (norepinephrine-driven vasoconstriction) and the dose-response relationship seen in some patients, the connection between stimulants and Raynaud’s is well-supported even if we lack a precise incidence number from a controlled trial.

Managing Raynaud’s While Treating ADHD

If you develop Raynaud’s symptoms on Adderall or a similar stimulant, you and your prescriber have several options. The simplest is to stop or reduce the dose of the stimulant. As discussed earlier, this resolves symptoms in many cases. But stopping is not always practical or desirable, especially if the medication is making a meaningful difference in your daily functioning.

Switching to a different ADHD medication is another route. The systematic review found that methylphenidate and amphetamines were the most commonly implicated drugs, with atomoxetine involved only rarely.³ Atomoxetine is a norepinephrine reuptake inhibitor (not a stimulant), so it still acts on norepinephrine, but it does not produce the same degree of peripheral vasoconstriction as amphetamines. Other non-stimulant ADHD medications like guanfacine and clonidine actually lower norepinephrine activity and are sometimes used for ADHD, particularly in children. Their vascular profile is essentially the opposite of stimulants, which is worth knowing if Raynaud’s is a concern.

For patients who stay on their stimulant, adding a vasodilator to counteract the constriction is a standard approach to managing Raynaud’s in general. Calcium channel blockers are the most commonly prescribed vasodilators for this purpose.⁸ Their effect in primary Raynaud’s is modest, reducing attacks by roughly one to two per week compared to placebo.⁹ Their effectiveness for stimulant-related Raynaud’s specifically has not been studied in controlled trials, but the logic of using a vasodilator to counterbalance a vasoconstrictor-driven problem is straightforward.

Behavioral strategies also matter. Keeping your hands and feet warm, wearing insulated gloves, avoiding rapid temperature changes, limiting caffeine (another vasoconstrictor), and not smoking all reduce the frequency and severity of episodes. These measures are not dramatic, but for mild stimulant-related Raynaud’s, they can be enough to make the condition manageable without medication changes.

Which ADHD Drugs Carry the Highest Risk

Not all ADHD medications are equally implicated. The FDA adverse-event analysis found that lisdexamfetamine had the strongest signal, with a reporting odds ratio of about 25, followed by methylphenidate at about 8.¹ Adderall (mixed amphetamine salts) falls in the same pharmacological family as lisdexamfetamine and dextroamphetamine and would be expected to carry a similar level of risk, though it was not broken out separately in that particular analysis.

Why might lisdexamfetamine show a higher signal than methylphenidate? The drugs work on overlapping but slightly different neurotransmitter pathways. Amphetamines both block reuptake and actively push norepinephrine and dopamine out of nerve terminals, giving them a more potent effect on peripheral norepinephrine levels. Methylphenidate mostly blocks reuptake without the active release component, which may explain the somewhat lower signal. But both drug classes clearly carry the risk.

Atomoxetine, the non-stimulant norepinephrine reuptake inhibitor, has been reported in a small number of cases but is implicated far less often.³ This could mean it genuinely carries lower risk, or it could partly reflect the fact that far fewer people take atomoxetine compared to stimulants, so fewer adverse events would be expected regardless. The evidence here is thin enough that drawing firm comparative conclusions is hard.

Who Is Most Vulnerable

The published literature on this topic does not include large enough studies to establish precise risk factors with confidence. But patterns emerge from the case reports. People who already have some degree of cold sensitivity or a family history of Raynaud’s are likely more susceptible, because their peripheral vessels are already primed to overreact. Patients with autoimmune connective tissue diseases like scleroderma or lupus are at higher risk for Raynaud’s in general, and adding a vasoconstrictor medication on top of an already-fragile vascular system raises the stakes considerably.

Women are more likely than men to have primary Raynaud’s in the general population, and several of the published stimulant-related cases involve female patients, though the literature is too small to confirm a clear sex-based risk difference for the drug-induced form specifically. Cold climates and occupations involving vibrating tools (like construction work) are well-known amplifiers of Raynaud’s, and they would logically compound the vascular stress caused by stimulant medication.

Smoking deserves special mention. Nicotine is itself a potent vasoconstrictor, and combining it with an amphetamine doubles down on the constriction signal reaching your peripheral arteries. If you smoke and take a stimulant, you are asking your finger and toe arteries to fight two vasoconstrictor signals at once.

Monitoring and When to Seek Help

If you start a stimulant and notice that your fingers or toes are turning white or blue with cold exposure more than they used to, or that numbness and tingling in your extremities have become a new feature of your daily life, bring it up with your prescriber. Early, mild episodes are the time to make management decisions, not after tissue damage has occurred.

For clinicians monitoring patients on stimulants, asking about cold sensitivity and color changes in the extremities at follow-up visits is a low-effort screen that can catch the problem early. Infrared thermography, a non-invasive imaging technique that maps skin surface temperature, has emerged as a tool for evaluating microvascular dysfunction in Raynaud’s patients and shows strong sensitivity and specificity in detecting the abnormal temperature patterns characteristic of the condition.¹⁰ This is not standard practice for every person on Adderall, but for someone with borderline or ambiguous symptoms, it can help confirm whether clinically meaningful vascular changes are occurring.

Red flags that should prompt urgent evaluation include persistent discoloration that does not resolve after warming, open sores or ulcers on fingertips or toes, severe pain at rest, and skin that looks dusky or blackened. These suggest that the blood supply has been compromised beyond simple vasospasm and that tissue is at risk. Fortunately, reaching that point is rare, and most patients who develop stimulant-related Raynaud’s have mild, episodic symptoms that respond well to straightforward management adjustments.

1
Nature (Scientific Reports). A comprehensive study on drug-related Raynaud’s phenomenon based on the FDA adverse event reporting system
2
PubMed Central. Raynaud’s phenomenon during treatment with lisdexamfetamine: risk of cerebral vasospasm?
3
PubMed. Raynaud Syndrome Associated with Medication for Attention-Deficit/Hyperactivity Disorder: A Systematic Review
4
The Primary Care Companion for CNS Disorders. Rare Side Effects of Stimulants: Raynaud’s Phenomenon
5
PubMed. Association between central nervous system stimulants used to treat attention deficit hyperactivity disorder (ADHD) and Raynaud’s phenomenon: A scoping review
6
Journal of Clinical Rheumatology. Methylphenidate and Dextroamphetamine-Induced Peripheral Vasculopathy
7
PubMed. Peripheral vascular manifestation in patients receiving an amphetamine analog: A case series
8
PubMed Central. Calcium channel blockers for primary and secondary Raynaud’s phenomenon
9
PubMed Central. Calcium channel blockers for primary Raynaud’s phenomenon
10
PubMed Central. Infrared thermography for the diagnosis and monitoring of Raynaud’s phenomenon: current evidence and future directions